Clinical Trial Update: Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD [Phase 2]

View source ↗

Summary

Open-label Phase 2 pilot study of TG100801 for choroidal neovascularization due to age-related macular degeneration has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• TG100801

Snippet

Sponsor: TargeGen | Conditions: Macular Degeneration, Choroidal Neovascularization | Phase 2 | Status: TERMINATED